EMEA-002025-PIP04-19
Key facts
| Active substance |
Tabelecleucel
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0490/2020
|
| PIP number |
EMEA-002025-PIP04-19
|
| Pharmaceutical form(s) |
Dispersion for injection
|
| Condition(s) / indication(s) |
Treatment of Epstein-Barr virus associated post-transplant lymphoproliferative disorder
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Pierre Fabre Médicament
E-mail: medical_information@pierre-fabre.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|